SLC5A2 and type 2 diabetes mellitus: In the AACE and ACE position statement (2016), after the review of more than 80 DKA cases from the literature (including both events involving SGLT2-i drugs and those occurring before their introduction), it was found that in patients treated with SGLT-2 inhibitors, DKA was more frequent in insulin-deficient subjects such as those with T1DM and including latent autoimmune diabetes in adults (LADA), but cases have also occurred in some patients with longstanding T2DM.